ALTO-207 in Adults With Treatment-resistant Depression (TRD)
← catalyst calendarNCT07553637 · readout ≤ 468 d
Sponsored by Alto Neuroscience (industry) · ANRO — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
178estimated
Sites
48
Countries
United Kingdom, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | May 2026 | estimated | When the study began enrolling |
| Primary completion | Nov 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-04-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Treatment-resistant Depression (TRD)
Interventions
- Drug: ALTO-207
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFChange in the MADRS total score
measured Change from baseline up to 8 weeks
Permalink · ANRO's whole pipeline · Catalyst calendar · Every registered study · What changed